Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBS 004

Next Previous
X
Search
Drug Profile

CBS 004

Alternative Names: ANB-101; CBS-004

Latest Information Update: 22 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Capella BioScience
  • Developer Centessa Pharmaceuticals
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action CLEC4C protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cutaneous lupus erythematosus; Systemic lupus erythematosus; Systemic scleroderma

Most Recent Events

  • 12 Apr 2024 AnaptsyBio has patents pending for antibody sequence of ANB 101 and its variants, methods of use and related matters in various countries (AnaptysBio Form 10-K)
  • 11 Mar 2024 Anaptys plans a clinical trial for in USA in 2024
  • 27 Nov 2023 Centessa Pharmaceuticals announces intention to submit IND for autoimmune diseases to US FDA in the fourth quarter of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top